Channel Therapeutics Corporation (CHRO) Stock Overview
Explore Channel Therapeutics Corporation’s financial performance, market position, analyst ratings, and future outlook.
Channel Therapeutics Corporation (CHRO)
Key Financials
Key Financials
Market Cap
8.9M
P/E Ratio
-0.05
EPS (TTM)
$-12.00
ROE
-1.64%
CHRO Stock Analysis & Investment Overview (AMEX)
Our AI-powered analysis of Channel Therapeutics Corporation (AMEX: CHRO) gives investors deep insight into how the stock performs on the AMEX exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Channel Therapeutics Corporation's AMEX-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CHRO on the AMEX shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $3.13 for the AMEX listing.
Key metrics behind Channel Therapeutics Corporation's AMEX-traded stock include a P/E ratio of -0.05 and a market capitalization of 8.9M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CHRO on the AMEX.